TotalMarketCap

Relay Therapeutics

RLAYNasdaq United StatesHealth CareBiotechnology: Biological Products (No Diagnostic Substances)

Market cap

$3.759 B

$17.01 -5.66%

Close of 6 Nov 2026

As of 6 Nov 2026, Relay Therapeutics (RLAY) has a market capitalization of $3.76B. Market cap measures the value of outstanding equity at market prices; company totals combine applicable share classes. Prices and market caps come from Nasdaq, with financial fundamentals from SEC filings. See sources and calculation details.

Revenue

$15.4M

#3046 by revenue

Earnings

-$276.5M

Loss-making

Shares outstanding

220,959,470

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 163 →
  1. #23CRISPR TherapeuticsCRSP$4.71B
  2. #24Adaptive BiotechnologiesADPT$4.35B
  3. #25Relay TherapeuticsRLAY$3.76B
  4. #26Iovance BiotherapeuticsIOVA$3.49B
  5. #27Tarsus PharmaceuticalsTARS$3.33B

What if Relay Therapeutics were worth as much as…

Open the what-if tool →

Gold $28.2T

$127,792.10

Per share 7,513× higher

Bitcoin $1.53T

$6,914.61

Per share 407× higher

Apple $5.02T

$22,700.01

Per share 1,335× higher

Or at a round number

$5.00B$10.0B$20.0B$50.0B

Where these numbers come from

Share counts and financials for Relay Therapeutics are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Read the methodology.